ReviewImmunoTargets and therapy2025
Understanding and Managing Hyper IgE Syndromes.
Review in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyper-IgE syndromes represent an increasingly recognized and heterogeneous group of disorders characterized phenotypically by eczema, recurrent infections, and markedly elevated serum IgE levels. The identification of novel molecular defects in recent years has complicated definitive diagnosis, underscoring the genetic and clinical diversity of this group. In addition to immunological abnormalities, non-immunological manifestations-particularly those affecting connective tissue-contribute to significant comorbidities. The primary objectives of management are to control infections, prevent long-term complications, and improve quality of life. In this review, we summarize the clinical and laboratory features of disorders currently classified under hyper-IgE syndromes according to the most recent International Union of Immunological Societies framework and provide perspectives on their management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.